A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Author: Clot Connect

  • Warfarin Failure

    Stephan Moll, MD writes… Occasionally, recurrent DVT or PE occur in spite of warfarin therapy, particularly in patients with (a) fluctuating and sub-therapeutic INRs, (b) lupus anticoagulant/ antiphospholipid antibody (APLA) syndrome or (c) cancer.

  • Top 10 Publications on Thrombosis and Anticoagulation from 2012

    Stephan Moll writes… 2012 has been a year with significant progress in the field of venous thromboembolism and anticoagulation.  The three most noteworthy, clinically relevant developments were probably (a) the publication of the new ACCP (American College of Chest Physician) guidelines on antithrombotic therapy in February 2012; (b)  The FDA-approval of rivaroxaban (Xarelto) in November 2012 for the acute…

  • Apixaban (Eliquis) – Hospital Guideline

    Stephan Moll, MD writes… Apixaban (Eliquis®) is FDA-approved for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on  Dec 28th, 2012 is here).  Here is the management guideline for apixaban

  • Xarelto (Rivaroxaban) – Hospital Guideline

    Stephan Moll, MD writes… Xarelto® is FDA approved for treatment of venous thromboembolism (VTE), prevention of VTE after hip and knee replacement  surgery, and for atrial fibrillation.   A number of practical management questions are encountered by physicians, pharmacists, and other health care professional taking care of patients on Xarelto®, such as (a) dosing in…

  • FDA Approval for Apixaban (Eliquis) for A. Fib.

    Stephan Moll, MD writes… Today (Dec 28th, 2012) the FDA approved apixaban for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation, based on the ARISTOTLE study [ref 1].  The FDA press release is here.

  • Does Aspirin Prevent Recurrent DVT and PE? – ASPIRE Trial

    Stephan Moll, MD writes… Well, it is not clear whether it does.  A clinically relevant study (ASPIRE study) was published this week (Nov 22nd,2012) in the N Engl J Med  [ref 1].  In patients who had a previous unprovoked (= idiopathic) DVT or PE and who had completed standard length (often considered to be 3-6 months)…

  • Xarelto (Rivaroxaban): FDA Approved for DVT and PE Treatment

    Stephan Moll, MD writes… Today is a very exciting day for patients and health care professionals: the oral anticoagulant Xarelto® (rivaroxaban) was FDA approved today (Nov 2nd, 2012) for the use in patients with DVT and PE – for the acute treatment of DVT and PE, as well as for the secondary long-term prevention of…

  • TTP with I.V. Use of Pain Medication OpanaER

    Stephan Moll, MD writes…  The CDC published an alert on Oct 26th, 2012, that they are investigating 12 cases of TTP (thrombotic thrombocytopenic purpura) in drug users who injected intravenously the opioid pain medication Opana ER® (oxymorphone extended-release), a medication made as a tablet and meant for oral use. The tablet was pulverized by the drug…